This is a single arm, 24 weeks, pilot trial. All patients will be treated with standard of care plus Belimumab (at a dose of 10 mg per kilogram of body weight) .~The primary endpoint is the proportion of LLDAS in week 24.
To investigate the efficacy of belimumab in early SLE patients (disease duration less than 6 months).